Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background: Circulating microRNAs (miRs) may be promising biomarkers for several diseases. We previously found that miR-122 can function as a biomarker for non-alcoholic fatty liver disease (NAFLD). However, little is known regarding the time course of circulating miR-122 levels during the development of NAFLD. Here, we examined circulating miR-122 levels using a rat model of NAFLD. Methods: To clarify changes in serum levels of miR-122 during development of NAFLD, experimental rats were fed a high-fat diet (HFD) for 2-10. weeks, while control rats received standard chow. Serum and liver tissue was collected from all animals at 2, 6, and 10. weeks of feeding. Clinical laboratory parameters (cholesterol, TG, AST, ALT, NEFA) were determined by biochemistry analyzer. Hepatic lipid accumulation was estimated by Oil red O staining. Circulating miR-122 levels were then measured by real-time polymerase chain reaction. Results: Over the 10. weeks of feeding, body weight, total liver lipids, and liver and serum triacylglycerol were increased in the HFD group compared to the control group. However, no significant changes in serum alanine aminotransferase activity were observed, suggesting that NAFLD status was mild. In contrast, we observed drastic up-regulation of circulating miR-122 levels. Our findings suggest that serum miR-122 level is indeed useful for assessing early NAFLD and might be superior to clinical markers traditionally used to monitor hepatic disease.

Original languageEnglish
Pages (from-to)267-271
Number of pages5
JournalClinica Chimica Acta
Volume446
DOIs
Publication statusPublished - 01-01-2015

Fingerprint

Liver
Longitudinal Studies
Rats
Serum
Biomarkers
High Fat Diet
Nutrition
Lipids
Alanine Transaminase
MicroRNAs
Fats
Nonesterified Fatty Acids
Rat control
Clinical laboratories
Biochemistry
Non-alcoholic Fatty Liver Disease
Real-Time Polymerase Chain Reaction
Triglycerides
Up-Regulation
Polymerase chain reaction

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

@article{b56b7f72786c4a2e94e9801197dc1f36,
title = "Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease",
abstract = "Background: Circulating microRNAs (miRs) may be promising biomarkers for several diseases. We previously found that miR-122 can function as a biomarker for non-alcoholic fatty liver disease (NAFLD). However, little is known regarding the time course of circulating miR-122 levels during the development of NAFLD. Here, we examined circulating miR-122 levels using a rat model of NAFLD. Methods: To clarify changes in serum levels of miR-122 during development of NAFLD, experimental rats were fed a high-fat diet (HFD) for 2-10. weeks, while control rats received standard chow. Serum and liver tissue was collected from all animals at 2, 6, and 10. weeks of feeding. Clinical laboratory parameters (cholesterol, TG, AST, ALT, NEFA) were determined by biochemistry analyzer. Hepatic lipid accumulation was estimated by Oil red O staining. Circulating miR-122 levels were then measured by real-time polymerase chain reaction. Results: Over the 10. weeks of feeding, body weight, total liver lipids, and liver and serum triacylglycerol were increased in the HFD group compared to the control group. However, no significant changes in serum alanine aminotransferase activity were observed, suggesting that NAFLD status was mild. In contrast, we observed drastic up-regulation of circulating miR-122 levels. Our findings suggest that serum miR-122 level is indeed useful for assessing early NAFLD and might be superior to clinical markers traditionally used to monitor hepatic disease.",
author = "Hiroya Yamada and Koji Ohashi and Koji Suzuki and Eiji Munetsuna and Yoshitaka Ando and Mirai Yamazaki and Hiroaki Ishikawa and Naohiro Ichino and Ryouji Teradaira and Shuji Hashimoto",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.cca.2015.05.002",
language = "English",
volume = "446",
pages = "267--271",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",

}

TY - JOUR

T1 - Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease

AU - Yamada, Hiroya

AU - Ohashi, Koji

AU - Suzuki, Koji

AU - Munetsuna, Eiji

AU - Ando, Yoshitaka

AU - Yamazaki, Mirai

AU - Ishikawa, Hiroaki

AU - Ichino, Naohiro

AU - Teradaira, Ryouji

AU - Hashimoto, Shuji

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Circulating microRNAs (miRs) may be promising biomarkers for several diseases. We previously found that miR-122 can function as a biomarker for non-alcoholic fatty liver disease (NAFLD). However, little is known regarding the time course of circulating miR-122 levels during the development of NAFLD. Here, we examined circulating miR-122 levels using a rat model of NAFLD. Methods: To clarify changes in serum levels of miR-122 during development of NAFLD, experimental rats were fed a high-fat diet (HFD) for 2-10. weeks, while control rats received standard chow. Serum and liver tissue was collected from all animals at 2, 6, and 10. weeks of feeding. Clinical laboratory parameters (cholesterol, TG, AST, ALT, NEFA) were determined by biochemistry analyzer. Hepatic lipid accumulation was estimated by Oil red O staining. Circulating miR-122 levels were then measured by real-time polymerase chain reaction. Results: Over the 10. weeks of feeding, body weight, total liver lipids, and liver and serum triacylglycerol were increased in the HFD group compared to the control group. However, no significant changes in serum alanine aminotransferase activity were observed, suggesting that NAFLD status was mild. In contrast, we observed drastic up-regulation of circulating miR-122 levels. Our findings suggest that serum miR-122 level is indeed useful for assessing early NAFLD and might be superior to clinical markers traditionally used to monitor hepatic disease.

AB - Background: Circulating microRNAs (miRs) may be promising biomarkers for several diseases. We previously found that miR-122 can function as a biomarker for non-alcoholic fatty liver disease (NAFLD). However, little is known regarding the time course of circulating miR-122 levels during the development of NAFLD. Here, we examined circulating miR-122 levels using a rat model of NAFLD. Methods: To clarify changes in serum levels of miR-122 during development of NAFLD, experimental rats were fed a high-fat diet (HFD) for 2-10. weeks, while control rats received standard chow. Serum and liver tissue was collected from all animals at 2, 6, and 10. weeks of feeding. Clinical laboratory parameters (cholesterol, TG, AST, ALT, NEFA) were determined by biochemistry analyzer. Hepatic lipid accumulation was estimated by Oil red O staining. Circulating miR-122 levels were then measured by real-time polymerase chain reaction. Results: Over the 10. weeks of feeding, body weight, total liver lipids, and liver and serum triacylglycerol were increased in the HFD group compared to the control group. However, no significant changes in serum alanine aminotransferase activity were observed, suggesting that NAFLD status was mild. In contrast, we observed drastic up-regulation of circulating miR-122 levels. Our findings suggest that serum miR-122 level is indeed useful for assessing early NAFLD and might be superior to clinical markers traditionally used to monitor hepatic disease.

UR - http://www.scopus.com/inward/record.url?scp=84929311817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929311817&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2015.05.002

DO - 10.1016/j.cca.2015.05.002

M3 - Article

C2 - 25958847

AN - SCOPUS:84929311817

VL - 446

SP - 267

EP - 271

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

ER -